These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32440564)

  • 1. Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.
    Chang RYK; Kwok PCL; Khanal D; Morales S; Kutter E; Li J; Chan HK
    Bioeng Transl Med; 2020 May; 5(2):e10159. PubMed ID: 32440564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Storage stability of inhalable phage powders containing lactose at ambient conditions.
    Chang RYK; Wallin M; Kutter E; Morales S; Britton W; Li J; Chan HK
    Int J Pharm; 2019 Apr; 560():11-18. PubMed ID: 30710661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
    Lin Y; Yoon Kyung Chang R; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Int J Pharm; 2020 Dec; 591():119952. PubMed ID: 33059012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of storage temperature on the stability of spray dried bacteriophage powders.
    Leung SSY; Parumasivam T; Nguyen A; Gengenbach T; Carter EA; Carrigy NB; Wang H; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
    Eur J Pharm Biopharm; 2018 Jun; 127():213-222. PubMed ID: 29486303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.
    Leung SSY; Parumasivam T; Gao FG; Carter EA; Carrigy NB; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
    Int J Pharm; 2017 Apr; 521(1-2):141-149. PubMed ID: 28163231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriophage Encapsulation Using Spray Drying for Phage Therapy.
    Malik DJ
    Curr Issues Mol Biol; 2021; 40():303-316. PubMed ID: 32678066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of Formulation Components and Environmental Humidity on Spray-Dried Phage Powders for Treatment of Respiratory Infections Caused by
    Yan W; He R; Tang X; Tian B; Liu Y; Tong Y; To KKW; Leung SSY
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Resolution Nanoscale Probing of Bacteriophages in an Inhalable Dry Powder Formulation for Pulmonary Infections.
    Khanal D; Chang RYK; Morales S; Chan HK; Chrzanowski W
    Anal Chem; 2019 Oct; 91(20):12760-12767. PubMed ID: 31539468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
    Chang RYK; Chen K; Wang J; Wallin M; Britton W; Morales S; Kutter E; Li J; Chan HK
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix.
    Vandenheuvel D; Meeus J; Lavigne R; Van den Mooter G
    Int J Pharm; 2014 Sep; 472(1-2):202-5. PubMed ID: 24950368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.
    Chang RY; Wong J; Mathai A; Morales S; Kutter E; Britton W; Li J; Chan HK
    Eur J Pharm Biopharm; 2017 Dec; 121():1-13. PubMed ID: 28890220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
    Li M; Chang RYK; Lin Y; Morales S; Kutter E; Chan HK
    Int J Pharm; 2021 Mar; 596():120200. PubMed ID: 33486032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trileucine and Pullulan Improve Anti-Campylobacter Bacteriophage Stability in Engineered Spray-Dried Microparticles.
    Carrigy NB; Liang L; Wang H; Kariuki S; Nagel TE; Connerton IF; Vehring R
    Ann Biomed Eng; 2020 Apr; 48(4):1169-1180. PubMed ID: 31845128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.
    Chan HK; Chang RYK
    J Aerosol Med Pulm Drug Deliv; 2022 Apr; 35(2):73-82. PubMed ID: 34967686
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.
    Lin Y; Quan D; Chang RYK; Chow MYT; Wang Y; Li M; Morales S; Britton WJ; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2021 Jan; 158():166-171. PubMed ID: 33253892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of IgG1 in spray-dried powders for inhalation.
    Schüle S; Schulz-Fademrecht T; Garidel P; Bechtold-Peters K; Frieb W
    Eur J Pharm Biopharm; 2008 Aug; 69(3):793-807. PubMed ID: 18477504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
    Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
    Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
    Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
    Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.